Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia
Open Access
- 31 March 2012
- journal article
- Published by Elsevier BV in Experimental Hematology
- Vol. 40 (3), 216-227
- https://doi.org/10.1016/j.exphem.2011.11.006
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Clinical and biological significance of RAS mutations in multiple myelomaLeukemia, 2008
- Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and LymphomasPLOS ONE, 2008
- AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center MalignanciesCancer Cell, 2008
- Genetic events in the pathogenesis of multiple myelomaBest Practice & Research Clinical Haematology, 2007
- N-RASandK-RASgene mutations in Brazilian patients with multiple myelomaLeukemia & Lymphoma, 2006
- Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumorsPublished by American Society of Hematology ,2005
- Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non‐functional variant transcriptBritish Journal of Haematology, 2003
- An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growthOncogene, 2003
- High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosisHuman Mutation, 2001
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 1985